Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Top Cited Papers
- 1 March 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 9 (3), 370-383
- https://doi.org/10.1158/2159-8290.cd-18-0774
Abstract
Background: Preclinical models showed that blocking PD-1/PD-L1 pathways enhanced anti-leukemic responses. Azacitidine up-regulates PD-1 and interferon-gamma signaling. Methods: In this single arm trial, patients with relapsed/refractory (R/R) AML were treated with azacitidine 75mg/m2 Days 1-7 intravenously/subcutaneously with nivolumab 3mg/kg intravenously on Day 1 and 14, every 4-6 weeks. Findings: Seventy-patients were treated. The median age was 70-years (range,22-90). The median number of prior therapies was 2 (range,1-7). The overall response rate (ORR) was 33% including 15 (22%) complete remission (CR)/complete remission with insufficient recovery of counts (CRi), 1 partial response, and 7 patients with hematologic improvement (HI) maintained >6 months. Six-patients (9%) had stable disease >6 months. The ORR was 58% and 22%, in HMA-naive (n=25) and HMA pre-treated (n=45) patients, respectively. Grade 3-4 immune-related adverse events occurred in 8 (11%) patients. Pretherapy bone marrow and peripheral blood CD3 and CD8 were significantly predictive for response on flow-cytometry. CTLA-4 was significantly up-regulated on CD4+Teff in non-responders after 2 and 4 doses of nivolumab. Interpretation: Azacitidine-nivolumab therapy produced an encouraging response rate and overall survival in patients with R/R-AML, particularly in HMA-naive and Salvage-1 patients. Pretherapy bone marrow aspirate and peripheral blood CD3 percentage may be biomarkers for patient selection.Keywords
Other Versions
Funding Information
- MD Anderson Cancer Center (CA016672)
- MD Anderson Cancer Center (CA100632)
This publication has 33 references indexed in Scilit:
- Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemiaBlood, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blastsBlood, 2009
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia modelBlood, 2009
- Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemiaClinical and Experimental Immunology, 2009
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 2008
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003